The Blood and Marrow Transplant Program support cross-disciplinary research into the molecular and genetic underpinnings of hematological disorders, improving patient outcomes through clinical research into new treatments and complementary therapies. The program is developing new ways to boost the immune tolerance of transplanted blood or marrow-derived stem cells while its state-of-the-art laboratory is exploring novel cellular and vaccine-based therapies that target hematologic disease at its most basic origins. Clinical trials at the Stanford Cancer Center ensure the smooth translation of these research findings into the most advanced patient care available today.
For more information about our research efforts, please visit the Hematopoietic Cell Transplantation (HCT) Research Program.
Explore our Labs
Research projects in our laboratory are aimed at studying the biology of cell populations capable of inducing or suppressing graft vs host disease as well as cells capable of promoting a graft vs tumor effect.
The research interests are to understand the cellular and molecular basis of resistance to engraftment of transplanted allogeneic bone marrow (BM) cells and to understand the way in which BM grafts modify immune responses.
The Miklos laboratory focuses on B cell reconstitution after allogeneic hematopoietic cell transplantation and the serologic identification of minor histocompatibility antigens.